One JAK inhibitor is already available for vitiligo: ruxolitinib cream (Opzelura), which the FDA approved in July 2022 as the first pharmacologic treatment specifically for repigmentation. The bigger question most people are really asking is when oral JAK inhibitors and newer options will reach the market, and the answer is that the first oral option could arrive as early as 2026 or 2027.
What’s Available Right Now
Ruxolitinib cream is currently the only FDA-approved JAK inhibitor for vitiligo. It’s indicated for nonsegmental vitiligo in adults and adolescents aged 12 and older. The European Medicines Agency granted approval in April 2023 for the same age group, specifically for nonsegmental vitiligo with facial involvement. So if you’re in the U.S. or Europe, this treatment is already on the market and prescribed by dermatologists.
In clinical trials, about 30% of patients using ruxolitinib cream achieved at least 75% facial repigmentation by 24 weeks. That’s roughly four times the rate seen with a placebo cream. Results continued to improve beyond that point, which is important to understand: this isn’t a treatment where you see dramatic change in the first few weeks. Repigmentation builds gradually over months, and many dermatologists recommend committing to at least six months before judging effectiveness.
Getting Insurance to Cover Ruxolitinib Cream
Access to ruxolitinib cream often involves prior authorization, which means your insurance company reviews whether you meet certain criteria before agreeing to pay. A typical policy, like Cigna’s, requires all of the following: you’re at least 12 years old, you have nonsegmental vitiligo affecting 10% or less of your body surface area, a dermatologist is prescribing it, and you’ve already tried a high-potency topical steroid or a calcineurin inhibitor for at least 12 weeks without adequate results. Approvals are generally granted in six-month increments.
The requirement to try other treatments first can be frustrating, especially since those older options have limited evidence for vitiligo. But it’s a standard step insurers impose. If you haven’t yet tried a prescription-strength topical steroid or calcineurin inhibitor, expect your dermatologist to start there.
Oral JAK Inhibitors in the Pipeline
The treatment most people are watching is upadacitinib (Rinvoq), an oral JAK1 inhibitor made by AbbVie. It’s already approved for conditions like eczema and rheumatoid arthritis, and in October 2025, two phase 3 trials in vitiligo met their primary goals. At 48 weeks, patients taking 15 mg daily showed significant improvement in both total body and facial repigmentation. Full results and regulatory filings are expected in 2026, making this the leading candidate to become the first oral JAK inhibitor approved for vitiligo. If everything goes smoothly with regulatory review, approval could come in late 2026 or 2027.
This would be a meaningful shift. An oral pill treats vitiligo systemically, which matters most for people with widespread patches that are impractical to cover with a cream twice daily. The cream is limited to smaller areas, and many insurers cap coverage at 10% body surface area involvement. A pill could fill that gap.
Two other oral JAK inhibitors are also in development. Povorcitinib, another JAK1 inhibitor, completed a phase 2 trial with 171 patients and showed continuous improvement through 52 weeks. Patients on the treatment saw meaningful total body repigmentation compared to a slight worsening in the placebo group. It hasn’t entered phase 3 yet, so it’s further behind upadacitinib. Ritlecitinib, which targets JAK3 and a related enzyme family, showed significant facial repigmentation in a phase 2b trial of 364 patients, with the best results at higher doses. Pfizer already sells ritlecitinib for alopecia areata, so the drug itself has regulatory history, but vitiligo-specific approval would require additional trials.
Safety Differences Between Cream and Pills
The reason a topical JAK inhibitor reached the market first isn’t just about timing. It’s about safety. When you apply ruxolitinib as a cream, very little enters your bloodstream. The most common side effects are mild: application-site irritation, some itching, or occasional acne at the treatment site (around 5% of users). Serious infections in clinical trials were rare and weren’t linked to the cream itself.
Oral JAK inhibitors are a different story. Because they work throughout your entire body, they carry a broader side effect profile. Common issues include upper respiratory infections, cold-like symptoms, headache, and acne. More seriously, the FDA placed a boxed warning on oral JAK inhibitors as a class after a large post-marketing study in rheumatoid arthritis patients over 50 found increased risks of blood clots, major cardiovascular events, and certain cancers compared to older biologic drugs. That warning was initially based on one specific drug but was extended to other oral JAK inhibitors, including upadacitinib, as a precaution.
Studies of upadacitinib in eczema patients, followed for nearly three years, haven’t shown an increased blood clot risk so far. But questions remain about long-term cancer and cardiovascular risks, particularly for older patients or those with pre-existing heart disease. For younger, otherwise healthy vitiligo patients, the risk-benefit calculation may look quite different than it did in the rheumatoid arthritis population that triggered the warning. Regulators will weigh this carefully during the approval process.
What This Means for Your Timeline
If you have limited vitiligo patches, especially on the face, ruxolitinib cream is available now and worth discussing with a dermatologist. Expect to navigate prior authorization and potentially try a steroid cream first, but the path to treatment is established.
If you have widespread vitiligo and are waiting for an oral option, upadacitinib is the closest candidate, with a realistic timeline of late 2026 to 2027 for potential approval. Povorcitinib and ritlecitinib are likely several years further out, as they still need to complete or begin phase 3 programs. Some dermatologists already prescribe oral JAK inhibitors off-label for vitiligo, using versions approved for other conditions, though insurance rarely covers this and out-of-pocket costs can exceed $5,000 per month.
The pipeline is the most active it has ever been. After decades with no FDA-approved vitiligo treatments at all, the first arrived in 2022, and at least one oral option is on track within the next two years.